170 related articles for article (PubMed ID: 20851072)
1. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.
Chen Z; Ayala P; Wang M; Fayad L; Katz RL; Romaguera J; Caraway N; Neelapu SS; Kwak LW; Simmons PJ; McCarty N
Stem Cell Res; 2010 Nov; 5(3):212-25. PubMed ID: 20851072
[TBL] [Abstract][Full Text] [Related]
2. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.
Jung HJ; Chen Z; McCarty N
Leuk Lymphoma; 2011 Jun; 52(6):1066-79. PubMed ID: 21599592
[TBL] [Abstract][Full Text] [Related]
3. Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells.
Medina DJ; Abass-Shereef J; Walton K; Goodell L; Aviv H; Strair RK; Budak-Alpdogan T
PLoS One; 2014; 9(4):e91042. PubMed ID: 24722054
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
[TBL] [Abstract][Full Text] [Related]
5. A subset of CD45+/CD19 - cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma.
Kim SM; Lee ST; Ryu KJ; Kim HJ; Kim SH; Ko YH; Kim WS; Kim SJ
Leuk Lymphoma; 2015; 56(11):3052-7. PubMed ID: 25739938
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
7. Targeting Wnt pathway in mantle cell lymphoma-initiating cells.
Mathur R; Sehgal L; Braun FK; Berkova Z; Romaguerra J; Wang M; Rodriguez MA; Fayad L; Neelapu SS; Samaniego F
J Hematol Oncol; 2015 Jun; 8():63. PubMed ID: 26048374
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
9. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.
Klanova M; Soukup T; Jaksa R; Molinsky J; Lateckova L; Maswabi BC; Prukova D; Brezinova J; Michalova K; Vockova P; Hernandez-Ilizaliturri F; Kulvait V; Zivny J; Vokurka M; Necas E; Trneny M; Klener P
Lab Invest; 2014 Jul; 94(7):806-17. PubMed ID: 24862967
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based therapy for mantle cell lymphoma.
Munger CM; Vose JM; Joshi SS
Int J Oncol; 2006 Jun; 28(6):1337-43. PubMed ID: 16685434
[TBL] [Abstract][Full Text] [Related]
11. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.
Wu B; Li J; Wang H; Wu Q; Liu H
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2197-2208. PubMed ID: 32040593
[TBL] [Abstract][Full Text] [Related]
12. CD45 expression in low-grade B-cell non-Hodgkin's lymphomas.
Carulli G; Cannizzo E; Zucca A; Buda G; Orciuolo E; Marini A; Petrini M
Leuk Res; 2008 Feb; 32(2):263-7. PubMed ID: 17692374
[TBL] [Abstract][Full Text] [Related]
13. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
[TBL] [Abstract][Full Text] [Related]
14. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
Wang M; Zhang L; Han X; Yang J; Qian J; Hong S; Lin P; Shi Y; Romaguera J; Kwak LW; Yi Q
Clin Cancer Res; 2008 Apr; 14(7):2154-60. PubMed ID: 18381957
[TBL] [Abstract][Full Text] [Related]
15. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis.
Saksena A; Yin CC; Xu J; Li J; Zhou J; Wang SA; Lin P; Tang G; Wang L; Wang M; Miranda RN; Medeiros LJ; Li S
Hum Pathol; 2019 Jul; 89():71-80. PubMed ID: 31054894
[TBL] [Abstract][Full Text] [Related]
16. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
[TBL] [Abstract][Full Text] [Related]
17. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
18. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
